Propanc Biopharma issues $33K convertible promissory note to GS Capital at 8% interest

Propanc Biopharma, Inc.

Company entered securities purchase agreement with GS Capital Partners on Aug 9, 2024 for $33,000 principal note at $30,000 purchase price.
Note matures Feb 2, 2025, bears 8% interest, convertible at $0.0017/share initially, adjustable to $0.001 if stock trades below $0.0014 for 5 days.
Company can prepay at 110% within 60 days, escalating to 125% after 120 days; no prepayment after 180 days.
Proceeds used for working capital; note issued under Section 4(a)(2) and Rule 506 of Regulation D.
Default events include failure to maintain OTC Markets listing, breach of covenants; interest rises to 24% on default.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.